---
title: "Key facts: Dupixent Japan approval; Sarclisa CHMP nod; IL‑33 COPD fails"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280859187.md"
description: "Sanofi's Sarclisa subcutaneous injector for multiple myeloma received a positive recommendation from the EMA CHMP, with EU decision pending and FDA review ongoing. Dupixent was approved in Japan for adults with moderate-to-severe bullous pemphigoid, showing promising trial results. However, Sanofi's late-stage IL-33 COPD trial failed to meet its primary endpoints, contrasting with positive data from competitors."
datetime: "2026-03-28T02:04:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280859187.md)
  - [en](https://longbridge.com/en/news/280859187.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280859187.md)
---

# Key facts: Dupixent Japan approval; Sarclisa CHMP nod; IL‑33 COPD fails

-   EMA CHMP recommended approval of Sanofi's Sarclisa subcutaneous on‑body injector for multiple myeloma after Phase 3 showed non‑inferiority to IV; EU decision pending and FDA review ongoing.12
-   Sanofi's Dupixent approved in Japan for adults with moderate-to-severe bullous pemphigoid after Phase 2/3 trial showed higher sustained remission and faster steroid tapering — growth driver for SAN.3
-   Sanofi said its late‑stage IL‑33 COPD trial missed endpoints. Trial failure contrasts with rival positive data; company confirmed the program did not meet primary goals.4

### Related Stocks

- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [688108.CN](https://longbridge.com/en/quote/688108.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [688480.CN](https://longbridge.com/en/quote/688480.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)

## Related News & Research

- [Sanofi says rare lung disease drug outperforms standard care in trial](https://longbridge.com/en/news/286810610.md)
- [Sanofi: Information concerning the total number of voting rights and shares - April 2026](https://longbridge.com/en/news/286946199.md)
- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)